Nurix Therapeutics宣布,其候选药物Bexobrutideg将在2026年欧洲血液学协会(EHA)大会上进行口头报告。这一进展标志着该药物在血液学领域的研究获得了重要认可,并将向全球血液学专家展示其最新的临床数据与研究成果。
Nurix Therapeutics宣布,其候选药物Bexobrutideg将在2026年欧洲血液学协会(EHA)大会上进行口头报告。这一进展标志着该药物在血液学领域的研究获得了重要认可,并将向全球血液学专家展示其最新的临床数据与研究成果。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.